Biofortuna Ltd, Liverpool, UK, has introduced AmpDry, a patent-pending, stabilized master mix for polymerase chain reaction (PCR) applications.
According to the company, the AmpDry hot-start master mix was developed to enable complete end-stage or real-time PCR assays to remain stable in a dry format at ambient temperatures for at least 12 months, eliminating the need for cold-chain shipping and storage.
The master mix also allows for the straightforward creation of stabilized assays, as oligonucleotides are combined with the AmpDry reagent and dispensed into PCR vessels, and then stabilized by controlled-air drying. Once the reagent is dried, the end-user adds the DNA sample to the stabilized reaction vessel prior to amplification and detection.
Available in both bulk and small volumes, the AmpDry master mix is suitable for use by commercial manufacturers and laboratory users. Biofortuna also offers full IVD contract manufacturing services using AmpDry. The company can customize the manufacturing process to match customer requirements and create bespoke, cost-effective, stabilized products, company officials say.
“This new technology will enable us to further support our IVD customers in the development of easy-to-use diagnostics, increasing laboratory productivity, and improving quality of clinical testing and patient care,” says Nick Ash, PhD, Biofortuna’s CEO.
Biofortuna is ISO13485 certified and registered with FDA. To learn more, visit Biofortuna.
